ACRS
NASDAQ
US
Aclaris Therapeutics, Inc. - Common Stock
$4.20
▲ +$0.06
(+1.45%)
Vol 940K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$326.1M
ROE
-102.8%
Margin
-900.0%
D/E
0.00
Beta
0.89
52W
$1–$3
Wall Street Consensus
15 analysts · Apr 20266
Strong Buy
7
Buy
2
Hold
0
Sell
0
Strong Sell
86.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%
Next Report
May 06, 2026
EPS Estimate: $-0.16
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.16 | — | — |
| Dec 2025 | $-0.15 | $-0.16 | $-0.01 |
| Sep 2025 | $-0.14 | $-0.12 | +$0.02 |
| Jun 2025 | $-0.14 | $-0.13 | +$0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $9.2M | $1.5M | $1.8M | $3.3M | $1.3M |
| Net Income | — | -$96.6M | -$15.1M | -$15.4M | -$14.6M | -$19.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -95.9% | -95.9% | -95.9% | -95.9% | -102.8% | -102.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -868.3% | -802.0% | -802.0% | -802.0% | -900.0% | -900.0% |
| Gross Margin | -4.1% | 10.2% | 10.2% | 10.2% | 4.0% | 4.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.88 | 3.88 | 3.88 | 3.88 | 3.92 | 3.92 |
Key Ratios
ROA (TTM)
-72.4%
P/S (TTM)
20.72
P/B
1.7
EPS (TTM)
$-1.38
CF/Share
$-1.65
Rev Growth 3Y
+40.4%
52W High
$3.48
52W Low
$1.05
$1.05
52-Week Range
$3.48
Financial Health
Free Cash Flow
-$13.2M
Cash
$20.0M
As of Dec 31, 2025
How does ACRS compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ACRS valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
20.7
▲
319%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
1.7
▼
20%
below
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ACRS profitability vs Pharmaceuticals peers
ROE
-102.8%
▼
89%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-900.0%
▼
1800%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
4.0%
▼
94%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-72.4%
▼
93%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
ACRS financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
3.9
▲
17%
above
peers
(3.4)
vs Peers
vs Industry
Below avg
Beta
0.9
▼
5%
below
peers
(0.9)
vs Peers
vs Industry
Less volatile
ACRS fundamentals radar
ACRS
Peer median
Industry
ACRS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ACRS vs peers: key metrics
Latest News
No related news yet